| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3198615 | Journal of Allergy and Clinical Immunology | 2012 | 18 Pages |
Abstract
MP29-02 represents a novel therapy that demonstrated superiority to 2 first-line therapies for AR. Patients with moderate-to-severe SAR achieved better control, and their symptoms were controlled earlier with MP29-02 than with recommended medications according to guidelines.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Warner MD, Jonathan MD, Phil MD, Eli MD, Claus MD, PhD, David MD, Ullrich PD Dr rer nat, Jean MD, PhD,